Jessica Trinh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jessica Trinh has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Alejandra Casillas
Division of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine at UCLA, 200 Medical Plaza, Suite 420, Los Angeles, CA 90095, USA
1 shared publication - Arleen F. Brown
Division of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, USA
1 shared publication Ashlie A. Bernhisel
Mayo Clinic Alix School of Medicine (J.T.), Rochester, MN; and Department of Ophthalmology (A.A.B., C.B.N., M.M.S.), Mayo Clinic, Rochester, MN
1 shared publicationBowen Zhang
Brain and Spinal Cord Innovative Research Center, Tongji Hospital, Tongji University School of Medicine, Shanghai, China
1 shared publicationCherie B. O.D. Nau
Mayo Clinic Alix School of Medicine (J.T.), Rochester, MN; and Department of Ophthalmology (A.A.B., C.B.N., M.M.S.), Mayo Clinic, Rochester, MN
1 shared publicationChongchong Xu
Department of Biomedical Sciences, University of Illinois College of Medicine Rockford, Rockford, IL, USA
1 shared publication
Latest Publications
- 28 July 2025
- Published by Wolters Kluwer Health in Eye & Contact Lens: Science & Clinical Practice
- Vol. 51 (10) , 450-453
Intracorneal Hemorrhage Associated With Scleral Lens Wear
Scleral lenses have been shown to provide improved visual acuity and ocular surface protection in patients with corneal irregularities and ocular surface disease. However, scleral lens (SL) wear may lead to anterior ocular pathology owing to metabolic or mechanical stress. Most reports of SL-related complications have described microbial keratitis or hypoxia-related issues. There is limited literature describing complications caused by mechanical interactions, such as suction between the SL and ocular surface. This case report describes a patient with long-standing keratoconjunctivitis and keratoconus who developed intracorneal hemorrhage within 4 hr of completing application and removal training on the first day of SL wear.
- 28 July 2025
- Published by Wolters Kluwer Health in Eye & Contact Lens: Science & Clinical Practice
- Vol. 51 (10) , 450-453
Intracorneal Hemorrhage Associated With Scleral Lens Wear
Scleral lenses have been shown to provide improved visual acuity and ocular surface protection in patients with corneal irregularities and ocular surface disease. However, scleral lens (SL) wear may lead to anterior ocular pathology owing to metabolic or mechanical stress. Most reports of SL-related complications have described microbial keratitis or hypoxia-related issues. There is limited literature describing complications caused by mechanical interactions, such as suction between the SL and ocular surface. This case report describes a patient with long-standing keratoconjunctivitis and keratoconus who developed intracorneal hemorrhage within 4 hr of completing application and removal training on the first day of SL wear.
- Open Access
Community-Engaged Approaches for Improving the Inclusion of Diverse Communities in a Nutrition Clinical Trial
Background: Cardiometabolic disease (CMD) disproportionately affects African American/Black (AA) and Latino communities. CMD disparities are exacerbated by their underrepresentation in clinical trials for CMD treatments including nutritional interventions. The study aimed to (1) form a precision nutrition community consultant panel (PNCCP) representative of Latino and AA communities in Los Angeles to identify barriers and facilitators to recruitment and retention of diverse communities into nutrition clinical trials and (2) develop culturally informed strategies to improve trial diversity. Methods: A deliberative community engagement approach was used to form a PNCCP for the Nutrition for Precision Health (NPH) trial, part of the of the All of Us research initiative. The PNCCP included individuals that provide services for Latino and AA communities who met during 11 virtual sessions over 1 year. Discussion topics included enhancing recruitment and cultural acceptance of the NPH trial. We summarized CCP recommendations by theme using an inductive qualitative approach. Results: The PNCCP included 17 adults (35% AA, 47% Latino). Four thematic recommendations emerged: reducing structural barriers to recruitment, the need for recruitment materials to be culturally tailored and participant-centered, community-engaged trial recruitment, and making nutrition trial procedures inclusive and acceptable. We outlined the study response to feedback, including the constraints that limited implementation of suggestions. Conclusion: This study centers community voices regarding the recruitment and retention of AA and Latino communities into a nutrition clinical trial. It highlights the importance of community engagement early on in protocol development and maintaining flexibility to enhance inclusion of diverse communities in nutrition clinical trials.
Open AccessCommunity-Engaged Approaches for Improving the Inclusion of Diverse Communities in a Nutrition Clinical Trial
Background: Cardiometabolic disease (CMD) disproportionately affects African American/Black (AA) and Latino communities. CMD disparities are exacerbated by their underrepresentation in clinical trials for CMD treatments including nutritional interventions. The study aimed to (1) form a precision nutrition community consultant panel (PNCCP) representative of Latino and AA communities in Los Angeles to identify barriers and facilitators to recruitment and retention of diverse communities into nutrition clinical trials and (2) develop culturally informed strategies to improve trial diversity. Methods: A deliberative community engagement approach was used to form a PNCCP for the Nutrition for Precision Health (NPH) trial, part of the of the All of Us research initiative. The PNCCP included individuals that provide services for Latino and AA communities who met during 11 virtual sessions over 1 year. Discussion topics included enhancing recruitment and cultural acceptance of the NPH trial. We summarized CCP recommendations by theme using an inductive qualitative approach. Results: The PNCCP included 17 adults (35% AA, 47% Latino). Four thematic recommendations emerged: reducing structural barriers to recruitment, the need for recruitment materials to be culturally tailored and participant-centered, community-engaged trial recruitment, and making nutrition trial procedures inclusive and acceptable. We outlined the study response to feedback, including the constraints that limited implementation of suggestions. Conclusion: This study centers community voices regarding the recruitment and retention of AA and Latino communities into a nutrition clinical trial. It highlights the importance of community engagement early on in protocol development and maintaining flexibility to enhance inclusion of diverse communities in nutrition clinical trials.
- 28 August 2023
- Published by Springer Nature in Nature Metabolism
- Vol. 5 (9) , 1483-1493
Odour-imagery ability is linked to food craving, intake, and adiposity change in humans
It is well-known that food-cue reactivity (FCR) is positively associated with body mass index (BMI)1 and weight change2, but the mechanisms underlying these relationships are incompletely understood. One prominent theory of craving posits that the elaboration of a desired substance through sensory imagery intensifies cravings, thereby promoting consumption3. Olfaction is integral to food perception, yet the ability to imagine odours varies widely4. Here we test in a basic observational study whether this large variation in olfactory imagery drives FCR strength to promote adiposity in 45 adults (23 male). We define odour-imagery ability as the extent to which imagining an odour interferes with the detection of a weak incongruent odour (the ‘interference effect’5). As predicted in our preregistration, the interference effect correlates with the neural decoding of imagined, but not real, odours. These perceptual and neural measures of odour imagery are in turn associated with FCR, defined by the rated craving intensity of liked foods and cue-potentiated intake. Finally, odour imagery exerts positive indirect effects on changes in BMI and body-fat percentage over one year via its influences on FCR. These findings establish odour imagery as a driver of FCR that in turn confers risk for weight gain.
- 28 August 2023
- Published by Springer Nature in Nature Metabolism
- Vol. 5 (9) , 1483-1493
Odour-imagery ability is linked to food craving, intake, and adiposity change in humans
It is well-known that food-cue reactivity (FCR) is positively associated with body mass index (BMI)1 and weight change2, but the mechanisms underlying these relationships are incompletely understood. One prominent theory of craving posits that the elaboration of a desired substance through sensory imagery intensifies cravings, thereby promoting consumption3. Olfaction is integral to food perception, yet the ability to imagine odours varies widely4. Here we test in a basic observational study whether this large variation in olfactory imagery drives FCR strength to promote adiposity in 45 adults (23 male). We define odour-imagery ability as the extent to which imagining an odour interferes with the detection of a weak incongruent odour (the ‘interference effect’5). As predicted in our preregistration, the interference effect correlates with the neural decoding of imagined, but not real, odours. These perceptual and neural measures of odour imagery are in turn associated with FCR, defined by the rated craving intensity of liked foods and cue-potentiated intake. Finally, odour imagery exerts positive indirect effects on changes in BMI and body-fat percentage over one year via its influences on FCR. These findings establish odour imagery as a driver of FCR that in turn confers risk for weight gain.
- Top Cited Papers
- 1 September 2020
- Published by Elsevier in The American Journal of Surgery
- Vol. 220 (3) , 556-557
Anti-Asian sentiment in the United States – COVID-19 and history
- 1 September 2020
- Published by Elsevier in The American Journal of Surgery
- Vol. 220 (3) , 556-557
Top Cited PapersAnti-Asian sentiment in the United States – COVID-19 and history
- Open Access
- 25 March 2019
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 2 (2) , e201800268
Drug screening with human SMN2 reporter identifies SMN protein stabilizers to correct SMA pathology
Spinal muscular atrophy (SMA), the leading genetic cause of infant mortality, is caused by reduced levels of functional survival motor neuron (SMN) protein. To identify therapeutic agents for SMA, we established a versatile SMN2-GFP reporter line by targeting the human SMN2 gene. We then screened a compound library and identified Z-FA-FMK as a potent candidate. Z-FA-FMK, a cysteine protease inhibitor, increased functional SMN through inhibiting the protease-mediated degradation of both full-length and exon 7–deleted forms of SMN. Further studies reveal that CAPN1, CAPN7, CTSB, and CTSL mediate the degradation of SMN proteins, providing novel targets for SMA. Notably, Z-FA-FMK mitigated mitochondriopathy and neuropathy in SMA patient–derived motor neurons and showed protective effects in SMA animal model after intracerebroventricular injection. E64d, another cysteine protease inhibitor which can pass through the blood–brain barrier, showed even more potent therapeutic effects after subcutaneous delivery to SMA mice. Taken together, we have successfully established a human SMN2 reporter for future drug discovery and identified the potential therapeutic value of cysteine protease inhibitors in treating SMA via stabilizing SMN proteins.
- 25 March 2019
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 2 (2) , e201800268
Open AccessDrug screening with human SMN2 reporter identifies SMN protein stabilizers to correct SMA pathology
Spinal muscular atrophy (SMA), the leading genetic cause of infant mortality, is caused by reduced levels of functional survival motor neuron (SMN) protein. To identify therapeutic agents for SMA, we established a versatile SMN2-GFP reporter line by targeting the human SMN2 gene. We then screened a compound library and identified Z-FA-FMK as a potent candidate. Z-FA-FMK, a cysteine protease inhibitor, increased functional SMN through inhibiting the protease-mediated degradation of both full-length and exon 7–deleted forms of SMN. Further studies reveal that CAPN1, CAPN7, CTSB, and CTSL mediate the degradation of SMN proteins, providing novel targets for SMA. Notably, Z-FA-FMK mitigated mitochondriopathy and neuropathy in SMA patient–derived motor neurons and showed protective effects in SMA animal model after intracerebroventricular injection. E64d, another cysteine protease inhibitor which can pass through the blood–brain barrier, showed even more potent therapeutic effects after subcutaneous delivery to SMA mice. Taken together, we have successfully established a human SMN2 reporter for future drug discovery and identified the potential therapeutic value of cysteine protease inhibitors in treating SMA via stabilizing SMN proteins.